Table 5. Effect of elenagen followed by chemotherapy in breast cancer.
| Patient | Age | Tumor markers | CA15-3 u/ml, basal |
Prior therapy | Tumor response | |
|---|---|---|---|---|---|---|
| Elenagen only | Chemotherapy | |||||
| 05-001 | 46 | ER-; PR-; HER2- | 3.5 | RT, FDC, paclitaxel+ gemcitabine, cisplatin | SD 8 wks, | DC - SD 24 wk |
| 05-002 | 37 | ER-; PR-; HER2- BRCA1+ mutation | 139 | DC, RT, gemcitabine, cisplatin, avastin | PD | Eribulin - SD 12 wks; then cisplatin - SD 24 wk, |
| 05-005 | 37 | ER-; PR-; HER2- | 19.5 | FDC, docetaxel + cisplatin; gemcitabine +cisplatin; capecabin | SD 24 wks, | DC - SD 24 wks |
| 05-012 | 44 | ER-; PR-; HER2- | 9.5 | DC, paclitaxel | PD | DC - SD 12 wks, then eribulin+ trastuzumab SD - 20 wks |
| 05-013 | 51 | ER+, PR+, Her2- | 694 | RT, FDC, tamoxifen | PD | Anastarzol* - SD 28 wks |
| 05-014 | 43 | ER+; PR+; HER2- | 33 | FDC, RT, tamoxifen | SD 16 wks, | Tamoxifen - SD 20 wks* |
| 05-015 | 35 | ER-, PR-, Her2+ | 8 | FDC, RT, carboplatin+herceptin | SD 8 wks, | Eribulin - SD 20 wks |
SD – stable disease, PD – progressive disease; RT – radiation therapy, DC –doxorubicin+cyclophosphan; FDC – 5-fluorouracil+doxorubicin +cyclophosphan; * - still in the treatment (as of Dec 15th, 2016).